全文获取类型
收费全文 | 2463篇 |
免费 | 280篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 74篇 |
妇产科学 | 47篇 |
基础医学 | 407篇 |
口腔科学 | 42篇 |
临床医学 | 315篇 |
内科学 | 519篇 |
皮肤病学 | 126篇 |
神经病学 | 146篇 |
特种医学 | 276篇 |
外科学 | 175篇 |
综合类 | 84篇 |
一般理论 | 3篇 |
预防医学 | 197篇 |
眼科学 | 124篇 |
药学 | 167篇 |
中国医学 | 3篇 |
肿瘤学 | 87篇 |
出版年
2020年 | 21篇 |
2019年 | 35篇 |
2018年 | 29篇 |
2017年 | 25篇 |
2016年 | 24篇 |
2015年 | 34篇 |
2014年 | 46篇 |
2013年 | 61篇 |
2012年 | 59篇 |
2011年 | 85篇 |
2010年 | 64篇 |
2009年 | 86篇 |
2008年 | 72篇 |
2007年 | 124篇 |
2006年 | 68篇 |
2005年 | 67篇 |
2004年 | 69篇 |
2003年 | 61篇 |
2002年 | 85篇 |
2001年 | 84篇 |
2000年 | 87篇 |
1999年 | 63篇 |
1998年 | 107篇 |
1997年 | 89篇 |
1996年 | 69篇 |
1995年 | 64篇 |
1994年 | 52篇 |
1993年 | 51篇 |
1992年 | 53篇 |
1991年 | 52篇 |
1990年 | 55篇 |
1989年 | 72篇 |
1988年 | 61篇 |
1987年 | 52篇 |
1986年 | 54篇 |
1985年 | 42篇 |
1984年 | 35篇 |
1983年 | 34篇 |
1982年 | 25篇 |
1981年 | 22篇 |
1980年 | 26篇 |
1979年 | 22篇 |
1977年 | 29篇 |
1976年 | 27篇 |
1975年 | 25篇 |
1974年 | 37篇 |
1973年 | 26篇 |
1972年 | 22篇 |
1969年 | 30篇 |
1968年 | 23篇 |
排序方式: 共有2822条查询结果,搜索用时 125 毫秒
1.
2.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
3.
4.
D H Char J R Castro J M Quivey T L Phillips A R Irvine R D Stone S Kroll 《Ophthalmology》1989,96(12):1708-1715
The optimum radiation therapy for uveal melanoma is uncertain. Both helium ion irradiation and 125I brachytherapy have been used to treat this neoplasm. This investigation analyzed the control and complication rates of uveal melanomas treated with helium ions of 125I plaques. In both a retrospective and a prospective dynamically balanced study, the control rates appeared to be similar. There were more posterior segment complications after 125I plaques and more anterior segment complications, including neovascular glaucoma, after helium ion irradiation. The follow-up period is too short to draw definitive conclusions on the radiation complications. Overall, approximately 89% of eyes were retained and less than 4% of treated eyes were removed because of failure to control the tumor. 相似文献
5.
CM Reid M. Nelson P. Beckinsale P. Ryan LMH Wing LJ Beilin MA Brown GLR Jennings CI Johnston J. Marley JJ McNeil TO Morgan J. Shaw ID Steven MJ West 《Clinical and experimental pharmacology & physiology》1997,24(5):370-373
1. The present study aimed to determine the feasibility of conducting a 5 year cardiovascular outcome trial of the treatment of 6000 elderly hypertensive patients in Australian general practices. 2. General practitioners (GPs) were invited to participate by mail and personal follow-up. Patient records were reviewed to identify subjects for a blood pressure (BP) screening programme. Blood pressure was measured on three occasions and eligible subjects were included if the average BP was 160 mmHg systolic or 90 mmHg diastolic if systolic BP was 140 mmHg. 3. Seven hundred and forty-one GPs were approached and 89 were enrolled in the study (12% of mail invites and 75% of those receiving a personal contact). In 16 practices where screening was completed, 82 000 records were reviewed to identify 4% patients eligible for screening. Twenty-two per cent of eligible subjects attended screening. Of 1938 subjects screened, 180 (9%) had BP 5=160/90 mmHg. Forty-seven percent of subjects (n = 916) were receiving antihypertensive therapy and 184 (20%) were withdrawn from therapy. One hundred and sixteen (63%) of these subjects had BP return to study entry levels within 6 weeks. Fifty-seven newly diagnosed and 81 previously treated subjects were randomized (7% of the screened population). 4. Based on the high participation rate of GPs, the response rate of patients to attend a BP screening programme and the 7% randomization to screening ratio for entry into the study, the ANBP2 pilot study has demonstrated that it is feasible to recruit subjects from Australian general practices to a cardiovascular outcome trial. 相似文献
6.
7.
8.
9.
SUMMARY A young patient presenting with splenomegaly and hypersplenism was inadvertently found to have selective IgA deficiency. There were no symptoms of immunodeficiency and the patient responded well to splenectomy, with return of blood counts to normal without adverse effects. No other cause for the hypersplenism was found. We postulate selective IgA deficiency as a cause of splenomegaly and hypersplenism. 相似文献
10.
J Kantor K Irvine S Abrams P Snoy R Olsen J Greiner H Kaufman D Eggensperger J Schlom 《Cancer research》1992,52(24):6917-6925
We have previously reported the development of a recombinant vaccinia virus vaccine expressing the human carcinoembryonic antigen (CEA) gene, designated rV(NYC)-CEA. This construct has been shown to elicit specific anti-CEA immune responses and an antitumor effect in a murine tumor model. In the studies reported here, the safety and immunogenicity of this recombinant vaccinia virus were evaluated in a rhesus monkey model. Human CEA is a M(r) 180,000 glycoprotein expressed in approximately 90% of gastrointestinal carcinomas and in some breast and non-small cell lung carcinomas. This family also includes normal cross-reacting antigen (NCA). Rhesus monkeys, like humans, have some NCA on the surface of their granulocytes. Eight monkeys were immunized 3 or 4 times by skin scarification with the recombinant CEA vaccine and four monkeys received wild-type vaccinia virus as control. After three vaccinations, all rV(NYC)-CEA-vaccinated animals exhibited a strong anti-CEA antibody response as measured by enzyme-linked immunosorbent assay. The functional ability of these antibodies to mediate lysis of a CEA-bearing tumor cell was demonstrated using human effector cells. This response could be enhanced by interleukin 2. Cellular immunity to CEA was measured by delayed-type hypersensitivity upon intradermal challenge with purified CEA. Only those animals receiving the recombinant vaccine displayed significant anti-CEA responses. Furthermore, peripheral blood mononuclear cells from immunized monkeys were found to proliferate in response to CEA stimulation. All vaccinated monkeys developed local skin irritation at the site of the vaccination, regional lymphadenopathy, and low-grade fevers after immunization. Following immunization with rV(NYC)-CEA, the response was consistent with the usual constitutional symptoms seen with human smallpox virus immunization. Blood counts, differentials, and hepatic and renal chemistries remained normal in all animals throughout the study and for up to 1 year following the primary vaccination. No evidence of immunological cross-reactivity to NCA was found by either a fall in the granulocyte count or analyses for anti-NCA antibodies. Thus, the rV(NYC)-CEA vaccine appears to be safe in rhesus monkeys. The administration of a CEA recombinant vaccine to rhesus monkeys induces both a humoral and a cell-mediated immune response directed against human CEA. 相似文献